 |
|
|
|
 |
|
|
|
| Article 1 to 10 out of 142
|
|
-
LC Sciences and DNAVision form Strategic Marketing Alliance
(08 May 2008)
LC Sciences announced that it has entered into a strategic marketing alliance with DNAVision to increase accessibility to its custom microRNA profiling service and enhance both its customer and technical service to researchers in Europe. "We ......
-
Ablynx announces senior management change
(02 May 2008)
Ablynx has announced that Dr Hennie Hoogenboom will be stepping down from his position as Chief Scientific Officer and member of the Executive Committee. Dr Hoogenboom joined Ablynx in 2005 and has contributed significantly to building up the ......
-
Dyax Corp. Announces Intent to Close Belgium Research Facility
(30 Apr 2008)
Dyax Corp. announced that the Board of Directors of its Belgian subsidiary, Dyax SA, has initiated discussions with its 24 employees as it considers a possible closure of the Liege-based research facility. The closure option would allow for ......
-
Solvay Pharmaceuticals S.A. launches friendly bid to acquire Innogenetics
(29 Apr 2008)
Building on a successful R&D co-operation
Solvay Pharmaceuticals S.A., a subsidiary of Solvay, and Innogenetics N.V. jointly announced that Solvay Pharmaceuticals S.A. will make a conditional tender offer to acquire Innogenetics in a cash transaction valued at EUR 5.75 per share. ......
-
Galapagos licenses clinical rheumatoid arthritis program
(18 Apr 2008)
Galapagos NV and Enceladus Pharmaceuticals BV announced the in-licensing of Nanocort by Galapagos. Nanocort is a patented liposome-formulation of prednisolone to treat inflammatory diseases, in particular for the acute treatment of flares in ......
-
Galapagos appoints Piet Wigerinck as Senior VP Development
(15 Apr 2008)
Galapagos NV announced the appointment of Dr. Piet Wigerinck as Senior Vice President of Development. As a member of Galapagos' Executive Team, Dr. Wigerinck will oversee the development of Galapagos' drug candidates, including pre-clinical ......
-
Bausch & Lomb and Galapagos sign agreement to collaborate on ophthalmic disease research
(14 Apr 2008)
Bausch & Lomb and Galapagos NV announced that they have entered into a collaborative research agreement. Bausch & Lomb will have the exclusive option to license select Galapagos compounds as development candidates for therapeutic uses in ......
-
ThromboGenics Completes Patient Enrolment of MITI IV Trial, Evaluating the Safety and Preliminary Efficacy of Microplasmin
(11 Apr 2008)
ThromboGenics NV announced that it has completed patient enrolment for its Phase II MITI IV study. The primary purpose of this study is to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to acute ......
-
Innogenetics and Solvay Pharmaceuticals extend collaboration for biomarker discovery
(10 Apr 2008)
Innogenetics announced a 2-year extension of its longstanding research collaboration with Solvay Pharmaceuticals. Since November 1997, Solvay and Innogenetics have collaborated on a joint research program to explore new targets for Solvay's ......
-
UCB: Phase II results for CDP791 in non-small cell lung cancer support further clinical development
(01 Apr 2008)
UCB announced first results of its phase II exploratory study of CDP791, a specific VEGFR-2/KDR inhibitor, in combination with carboplatin and paclitaxel chemotherapy in first line non-small cell lung cancer (NSCLC). Positive improvements were ......
|
|
|
Top